Advice

In the absence of a submission from the holder of the marketing authorisation:

amivantamab (Rybrevant®) is not recommended for use within NHSScotland.

Indication under review: as monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

 

Download detailed advice234KB (PDF)

Download

Medicine details

Medicine name:
amivantamab (Rybrevant)
SMC ID:
SMC2638
Indication:

As monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
11 December 2023